background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

IL-2Rα

Interleukin 2 receptors (IL-2R) are cytokine receptors that are expressed on regulatory T cells (Tregs), CD8+ T cells, and natural killer cells. IL-2Rα is commonly found on Tregs, and when activated by its ligand IL-2, it contributes to Treg development, activity, and survival.1 In normal tissue, Tregs suppress T cells and control both innate and adaptive immune responses.2,3

CD, cluster of differentiation; GvHD, graft versus host disease; IL-2Rα, interleukin 2 receptor alpha.

References
1. Arenas-Ramirez N, et al. Trends Immunol. 2015;36:763-777. 2. Piccirillo CA, et al. Semin Immunol. 2004;16:81-88. 3. Maloy KJ, et al. J Exp Med. 2003;197:111-119. 4. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 5. Pol JG, et al. J Exp Med. 2020;217:e20191247. doi:10.1084/jem.20191247. 6. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03422627. Accessed 9/10/20.
Molecule
Modality4
Target4,5
Areas of Investigation6
Efavaleukin alfa (AMG 592)
Target4,5
IL-2Rα
Areas of Investigation6

CD, cluster of differentiation; GvHD, graft versus host disease; IL-2Rα, interleukin 2 receptor alpha.

References
1. Arenas-Ramirez N, et al. Trends Immunol. 2015;36:763-777. 2. Piccirillo CA, et al. Semin Immunol. 2004;16:81-88. 3. Maloy KJ, et al. J Exp Med. 2003;197:111-119. 4. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 5. Pol JG, et al. J Exp Med. 2020;217:e20191247. doi:10.1084/jem.20191247. 6. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03422627. Accessed 9/10/20.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.